Global Information
회사소개 | 문의 | 비교리스트

연조직 동종이식편 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

Soft Tissue Allografts Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 04월 상품 코드 707236
페이지 정보 영문
US $ 4,250 ₩ 5,050,000 PDF (Single User License)
US $ 4,750 ₩ 5,644,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,130,000 PDF (Site License)
US $ 7,500 ₩ 8,913,000 PDF (Corporate License)

연조직 동종이식편 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) Soft Tissue Allografts Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 04월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

육상경기나 스포츠 등에 기인한 부상에 사용되는 연조직 동종이식편 수요 증가, 연조직 수복 및 치환 기술의 발전, 고령자 인구 증가 등에 의해 연조직 동종이식편 시장 성장이 촉진되고 있습니다.

세계의 연조직 동종이식편(Soft Tissue Allografts) 시장을 조사했으며, 시장 개요, 종류·용도·최종사용자·지역별 시장 규모 추이와 예측, 시장 성장 촉진요인 및 저해요인 분석, 시장 기회, 경쟁 구도, 주요 기업 개요 등의 정보를 제공합니다.


제1장 서론

  • 조사 성과
  • 조사의 전제조건
  • 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 성장 촉진요인
    • 고령자 증가
    • 육상경기 및 기타 스포츠에서의 연조직 동종이식편 수요 증가
    • 연조직 치환 기술의 진보
  • 시장 성장 저해요인
    • 높은 치료비
    • 복잡한 상환 제도
  • Five Forces 분석
    • 구매자의 협상력
    • 공급 기업의 협상력
    • 신규 진출기업의 위협
    • 대체품의 위협
    • 경쟁 기업간 경쟁 관계

제5장 시장 세분화

  • 종류별
    • 연골 동종이식편
    • 건 동종이식편
    • 반월판 동종이식편
    • 치과 동종이식편
    • 기타
  • 용도별
    • 정형외과
    • 치과
    • 창상관리
    • 기타
  • 최종사용자별
    • 병원
    • 미용센터
    • 정형외과
    • 치과의원
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제6장 경쟁 구도

  • 기업 개요
    • Allergan Plc
    • B. Braun Melsungen AG
    • Conmed Corporation
    • Xtant Medical Holdings, Inc.
    • Alliqua BioMedical, Inc.
    • AlonSource Group
    • Becton Dickinson and Company
    • Arthrex, Inc.
    • Bone Bank Allografts
    • Osiris Therapeutics, Inc.
    • Integra LifeSciences Corporation
    • Stryker Corporation

제7장 시장 기회 및 향후 동향

LSH 19.09.20

The Soft Tissue Allografts Market was valued at USD 3,077.43 million in 2020, and it is expected to reach USD 4,724.46 million by 2026, registering a CAGR of 6.75% during the period of 2021-2026.

The outbreak of COVID-19 resulted in decreased public mobility and significantly impacted the therapeutic and surgical procedures, as the surgical procedures that are non-immediate and are being postponed to decrease the burden on healthcare infrastructure.

The outbreak of COVID-19 worldwide showed an impact on the market studied as surgical procedures kept on hold in order to prevent the spread of the COVID-19 virus. There is tremendous pressure on the hospitals and other healthcare centers in providing services to COVID-19 patients is also one of the factors that are inhibiting the hospitals in providing services.

The rising demand for soft tissue allografts in athletics and other sports is contributing largely to the market growth. Modern training regimens in athletics, field events, and a number of other contact sports like American football, require athletes to undergo intensive training sessions which are in practice more strenuous than the actual sport itself.

High-intensity training regimens are directly correlated with athletic performance improvement but excessive training also induces muscle and bone fatigue and often leads to injury. Consequently, injury prevalence among athletes has been increasing especially due to excessive training. The competitive nature of sports has spurred the demand among athletes for quick recovery and easily accessible modalities to treat musculoskeletal injuries.

Furthermore, osteoarthritis has a considerable impact on the individual patient, resulting in pain & disability, and the increasing prevalence of this diseases is expected to boost the market in near future.

For instance, as per data from the U.S. Department of Health and Human Services, 2018 reports an estimated 8.6 million sports injuries occur each year. The soft tissue market finds its grip behind technology development. While many companies in the market would like to release products that help market growth, awareness and growth in learning levels about these products will also play a big role. The level of awareness among the public, especially with the increase in internet access and easy access to social media, has increased. Over time, the soft tissue market will benefit from growing knowledge about products and processes.

Thus, demand for soft tissue allografts has been increasing in athletics and other contact sports, which in turn is fuelling the growth of the global soft tissue allografts market.

Key Market Trends

Cartilage Allograft is Expected to Hold Significant Market Share Over the Forecast Period

Cartilage allografts are the vital components in orthopedic surgical procedures such as joint reconstruction etc. Cartilage graft transplantation is frequently used in the treatment of chondral and osteochondral lesions, most commonly in the knee. These procedures can serve to improve the quality of life for those with pathology of the cartilage within joints and alleviate symptoms.

According to Ann Med Surg in his article published in 2020, estimate of the orthopedic surgery cancellation rate was approximately 82.0%, representing 6,295,041 of 7,677,515 cases. They concluded that if countries increased their normal surgical volumes by 20% after the pandemic, it would take about 45 weeks to clear the backlog of operations resulting from the disruption caused by COVID-19.

The scientific basis of Osteochondral allograft (OCA) is the transplantation of fully developed, or mature hyaline (joint) cartilage containing living cartilage cells ('chondrocytes') that survive the transplant and support the production of the cartilage matrix indefinitely.

As per the 2019 article published on Journal of Bone & Joint Surgery, Inc. by the researchers from Ohio State University College of Medicine, the conclusion of the study demonstrated that Osteochondral allograft (OCA) transplantation is a versatile treatment option for patients with cartilage and osteochondral defects and it is a uniquely useful treatment option for patients with large high-grade osteochondral defects and for athletes who have substantial incentives to return to sport as quickly as possible.

Arthrex, Inc. is one of the most renowned company involved in development of cartilage allografts. The company's portfolio includes several cartilage allografts namely Arthrex Meniscal Allograft Arthroplasty, Small Joint OATS (Osteochondral Autograft Transfer System) amongst others.

In March 2019, MTF Biologics expanded its portfolio with the launch of CartiMax viable cartilage allograft. CartiMax is a putty-like cartilage allograft designed to easily fill lesions in the knee, foot and ankle.

Thus, owing to the aforementioned factors, the market for Cartilage allografts segment is expected to grow significantly during the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

In North America, the market growth is majorly driven by factors, such as increasing prevalence of diabetic foot ulcers, better healthcare awareness program for diabetes, and an increasing number of surgical procedures on anterior cruciate ligament (ACL).

During COVID-19 pandemic 2020, in North America region, the specialty clinics, including dental practices and hospitals were shut down or their operations were limited, and some hospitals were being converted to containment facilities and treatment wards for COVID-19 patients.

In March 2020, in the United States, National Association for the Advancement of Orthotics and Prosthetics (NAAOP) issued an alert in which it was made clear that during the COVID-19 national emergency, state and local health authorities should consider orthotic and prosthetic practices as essential providers that must remain accessible to patients in need of orthotic and prosthetic care.

According to the Canadian Institute for Health Information 2019 report, the number of Canadians having joint replacements has increased over the past 5 years, with 130,000 surgeries being performed annually. There were almost 59,000 hip replacements and more than 70,000 knee replacements that were performed in Canada in 2017-2018. This represents an increase of 17.4% and 17%, respectively, over the last 5 years.

Therefore, the rising burden of diseases is creating tremendous opportunities for market players, and they are focusing on R&D activities, in order to bring new & reliable products in the market, thus, driving the market growth. For instance, In Feb 2020, Integra LifeSciences Holding Corporation has made the launch of AmnioExcel Plus Placental Allograft Membrane, that is the latest wound care offering to support soft tissue repair. Thus, owing to the aforementioned factors the market is expected to witness a high growth rate, over the forecast period.

Competitive Landscape

The Soft Tissue Allografts Market is moderately competitive and many of the global players are into the market. Some of the market players include Abbvie inc. (Allergan), Conmed Corporation, Becton Dickinson and Company, Smith & Nephew (Osiris Therapeutics Inc.), Integra LifeSciences Corporation, Stryker Corporation, Zimmer Biomet, Arthrex Inc., Direct Biologics and others. Also, new product launches from these players are augmenting the demand for these products.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Cases of Orthopedics and Dentistry Related with Aging
    • 4.2.2 Increasing Demand for Soft Tissue Allografts in Athletics and Other Sports
    • 4.2.3 Advancements in Soft Tissue Replacement
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
    • 4.3.2 Complicated Reimbursement and Regulatory Policies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Type
    • 5.1.1 Cartilage Allograft
    • 5.1.2 Tendon Allograft
    • 5.1.3 Meniscus Allograft
    • 5.1.4 Dental Allograft
    • 5.1.5 Other Types
  • 5.2 By Application
    • 5.2.1 Orthopedic
    • 5.2.2 Dentistry
    • 5.2.3 Wound Care
    • 5.2.4 Other Applications
  • 5.3 By End-User
    • 5.3.1 Hospitals
    • 5.3.2 Aesthetic Centres
    • 5.3.3 Orthopedic Clinics
    • 5.3.4 Dental Clinics
    • 5.3.5 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Abbvie inc. (Allergan)
    • 6.1.2 Conmed Corporation
    • 6.1.3 Xtant Medical Holdings Inc.
    • 6.1.4 Bone Bank Allografts
    • 6.1.5 Smith & Nephew(Osiris Therapeutics Inc.)
    • 6.1.6 Integra LifeSciences Corporation
    • 6.1.7 Stryker Corporation
    • 6.1.8 Zimmer Biomet
    • 6.1.9 Arthrex Inc.
    • 6.1.10 Direct Biologics


Back to Top
전화 문의